Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Medibio Limited announced that a DSM-V1 diagnosis will be included as a primary comparator for the purposes of assessing the efficacy of its depression algorithms, MEB-001. Medibio's clinical team proposed the International Neuropsychiatric Interview (MINI) as a diagnostic tool to satisfy the FDA's request whilst minimizing the burden of conduct for the validation trial. The FDA has confirmed that the MINI can be used to support the trial clinician diagnosis.